What investors can learn from LBT Innovations Limited's slump to a seven-month low

LBT Innovations Limited's (ASX:LBT) painful crash today on news that its French partner is pursuing another interest holds lessons for investors in the Australian life sciences sector.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The halving of LBT Innovations Limited's (ASX: LBT) share price this morning is a painful reminder for investors in the life sciences sector that having a global giant for a partner won't guarantee a happy ending.

The €3 billion ($A4.4 billion) market cap French laboratory equipment company, bioMérieux, has given word that it intends to terminate its exclusive deal with the ASX market minnow that involved licensing LBT's automated culture plate streaker in the next 12 months.

There are a few lessons investors can draw from this unfortunate experience that can be applied to LBT's other product opportunity.

While striking a partnership with a large partner is an important milestone for any small aspiring ASX life science company, it doesn't necessarily lower the riskiness of the investment. It just shifts the risks – usually from product risk (i.e. whether the technology works) to sales/distribution risks.

Getting a handle on the latter is not always easy but keeping an eye on quarterly sales figures will give one an idea on whether the product is gaining market traction. Anyone following the LBT story will know the automated streaker is not gaining sufficient traction when compared with LBT management's initial expectations in 2007 when the licensing deal was struck.

This brings me to the next important point. Global companies have their own (and often complicated) agenda and you can always count on them to pursue that first. This is because these companies have multiple products that are consistently competing for scarce resources within the organisation.

If a new product is not making sufficient inroads, the issue of moral hazard will become a major risk factor.

LBT's experience is not unique. If anything, such issues arise fairly regularly. Biota had to launch legal action against GlaxoSmithKline, while Johnson & Johnson initially dragged its feet in marketing a blood glucose testing kit from Universal Biosensors, Inc. (ASX: UBI) because it cannibalised on sales of Johnson & Johnson's existing product.

LBT's share price crashed 50% to 5 cents to a seven-month low before recovering slightly to 5.5 cents in late morning trade. LBT has received around $A13 million in various payments from bioMérieux over the years and will continue to be paid royalties for 2015.

The $7 million market cap innovator has another product line it is trying to commercialise. It has struck a joint venture with Swiss lab instrument company Hettich to develop an intelligent imaging platform.

Let's hope this partnership is more enduring.

Motley Fool contributor Brendon Lau does not own shares listed in this article.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »